| 000 | 01810 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518012822.0 | ||
| 264 | 0 | _c20190924 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a2473-9537 | ||
| 024 | 7 |
_a10.1182/bloodadvances.2018024364 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Chia-Ching | |
| 245 | 0 | 0 |
_aTransient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma. _h[electronic resource] |
| 260 |
_bBlood advances _c12 2018 |
||
| 300 |
_a3479-3482 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Retroviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aBrentuximab Vedotin |
| 650 | 0 | 4 |
_aCD4-Positive T-Lymphocytes _xcytology |
| 650 | 0 | 4 |
_aCD8-Positive T-Lymphocytes _xcytology |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV-1 _xgenetics |
| 650 | 0 | 4 |
_aHodgkin Disease _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoconjugates _xtherapeutic use |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 |
_aKi-1 Antigen _ximmunology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aRNA, Viral _xblood |
| 700 | 1 | _aThanh, Cassandra | |
| 700 | 1 | _aGibson, Erica A | |
| 700 | 1 | _aBall-Burack, Maya | |
| 700 | 1 | _aHogan, Louise E | |
| 700 | 1 | _aDescours, Benjamin | |
| 700 | 1 | _aJones, Norman | |
| 700 | 1 | _aCarvidi, Alexander B | |
| 700 | 1 | _aMunter, Sadie | |
| 700 | 1 | _aBakkour, Sonia | |
| 700 | 1 | _aBusch, Michael P | |
| 700 | 1 | _aMilush, Jeffrey M | |
| 700 | 1 | _aDeeks, Steven G | |
| 700 | 1 | _aHenrich, Timothy J | |
| 773 | 0 |
_tBlood advances _gvol. 2 _gno. 23 _gp. 3479-3482 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/bloodadvances.2018024364 _zAvailable from publisher's website |
| 999 |
_c29144034 _d29144034 |
||